Zymeworks Announces Participation in Upcoming Investor Conferences
July 30 2024 - 6:30AM
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing a diverse pipeline of novel, multifunctional
biotherapeutics to improve the standard of care for
difficult-to-treat diseases, today announced that management will
participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference: Zymeworks’ management
will participate in virtual one-on-one meetings and a fireside chat
on Tuesday, August 6 at 4:00 pm Eastern Time (ET).
- Wedbush PacGrow Healthcare Conference: Zymeworks’ management
will participate a panel discussion titled “ADCs and Old Lace:
Antibody Drug Conjugates” taking place on August 14, between 8:45 –
9:25 am ET, and will participate in one-on-one meetings on August
13-14 in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks’ mission is to
make a meaningful difference in the lives of people impacted by
difficult-to-treat cancers and other diseases. The Company’s
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using the
Company’s proprietary Azymetric™ technology. Zymeworks has entered
into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each exclusive
rights to develop and commercialize zanidatamab in different
territories. Zanidatamab is currently being evaluated in multiple
global clinical trials as a potential best-in-class treatment for
patients with HER2-expressing cancers. A Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA)
seeking accelerated approval for zanidatamab as a treatment for
previously-treated, unresectable, locally advanced, or metastatic
HER2-positive biliary tract cancer (BTC) has been accepted and
granted Priority Review. A BLA has also been accepted for review by
the Center for Drug Evaluation (CDE) of the National Medical
Products Administration (NMPA) in China. If approved, zanidatamab
would be the first HER2-targeted treatment specifically approved
for BTC in the U.S. and China. Zymeworks is rapidly advancing a
deep pipeline of product candidates based on its experience and
capabilities in both antibody-drug conjugates and multispecific
antibody therapeutics across multiple novel targets in indications
that represent areas of significant unmet medical need. In addition
to Zymeworks’ wholly owned pipeline, its therapeutic platforms have
been further leveraged through strategic partnerships with global
biopharmaceutical companies. For information about Zymeworks, visit
www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal InamdarDirector, Investor Relations(604)
678-1388 ir@zymeworks.com investors@zymeworks.com
Media Inquiries:
Diana PapoveSenior Director, Corporate Communications(604)
678-1388 ir@zymeworks.com media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024